-
Innovation Ranking
NewInnovation Ranking – SPX Flow Inc
SPX Flow Inc (SPX Flow) , a subsidiary of Lone Star Fund is a provider of engineered solutions. The company carries out the engineering, designing, manufacturing and marketing of various products and solutions related to turnkey projects across various industries. Its portfolio of products consists of pumps, valves, mixers, filters, air dryers, hydraulic tools, homogenizers, separators, and heat exchangers. The company sells its products through a network of distributors in the US and other countries. It serves food and beverage,...
-
Sector Analysis
Peak Flow Meters Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Peak Flow Meters Market Report Overview The peak flow meters market size was valued at $24.8 million in 2023. Factors such as the growing awareness of the devices in early diagnosis and monitoring of chronic respiratory diseases will drive the growth of the market. Thus, the peak flow meters market will grow at a CAGR of more than 3% from 2023 to 2033. A Peak Flow Meter is used for the diagnosis and monitoring of diseases such as asthma, and...
-
Company Insights
Innovation and Patenting activity of SPX Flow Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SPX Flow Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval Analysis for Shock
Overview How likely is it that the drugs in Shock will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Shock Overview Shock is a medical condition characterized by a significant and life-threatening...
-
Sector Analysis
NewSouth Korea Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2024 Update
GlobalData’s Tourism Source Market Insight: South Korea report provides a thorough insight into the South Korea's domestic and outbound tourism market. The report looks at the profiles of South Korean tourists and summarizes the key reasons that they travel. The report offers an in-depth analysis of traveler flows, spending patterns, main destination markets and current and future opportunities for tourism businesses seeking to tap into the South Korea's outbound travel market.
-
Product Insights
NewLikelihood of Approval Analysis for Arteriosclerosis
Overview How likely is it that the drugs in Arteriosclerosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arteriosclerosis Overview Arteriosclerosis refers to the thickening and hardening of arteries due to...
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval Analysis for Peripheral Artery Occlusive Disease (PAOD)
Overview How likely is it that the drugs in Peripheral Artery Occlusive Disease (PAOD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peripheral Artery Occlusive Disease (PAOD) Overview Peripheral artery occlusive...
-
Product Insights
NewLikelihood of Approval Analysis for Stroke
Overview How likely is it that the drugs in Stroke will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stroke Overview A stroke, also known as a cerebrovascular accident (CVA), is a...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.